Search

Search Constraints

You searched for: Author/Creator Schey, Steve

Search Results

1. Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience. (17th February 2017)

2. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Issue 6 (June 2019)

3. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Issue 12 (25th September 2020)

4. Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. (14th March 2021)

5. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. (14th March 2013)

6. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. (20th April 2015)